MedTrace Logo

Pemetrexed and Gemcitabine for Treatment Resistant Patients With Metastatic Colorectal Cancer and KRAS Mutations

NCT01109615 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2012-04-19

No results posted yet for this study

Summary

This study aims to investigate the efficacy and safety of the combination of pemetrexed and gemcitabine in heavily pre-treated, chemotherapy resistant colorectal cancer patients with KRAS mutations.

Conditions

Interventions

DRUG

Pemetrexed

400 mg/m2 on day 1 of a 3 weeks cycle

DRUG

Gemcitabine

1000 mg/m2 intravenously on day 1 and 8 of a 3 weeks cycle

Sponsors & Collaborators

  • Vejle Hospital

    lead OTHER

Principal Investigators

  • Anders Jakobsen, DMSc · Vejle Hospital

Study Design

Purpose
TREATMENT
Masking
NONE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-04-30
Primary Completion
2011-08-31
Completion
2012-03-31

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01109615 on ClinicalTrials.gov